Fraunhofer IZI Granted Manufacturing Authorization For Second GMP Facility
1/21/2014 11:08:15 AM
10 January 2014, the existing manufacturing authorization according to
Art. 13 of the German Drug Act (AMG) of the Fraunhofer Institute for Cell
Therapy and Immunology IZI was expanded to cover the first extension of the
existing cleanroom facility.
After extensive qualification and inspection by the Regional Council of Saxony, the
»Certificate of GMP-Compliance of a Manufacturer« was also updated. This seal of
approval doubles the institute's capacities to manufacture cell-based medicinal
products, or so-called »Advanced Therapy Medicinal Products« (ATMP).
Cell therapy products for clinical studies can now be produced on a total cleanroom
area of over 750 m² in sixteen cleanroom class B manufacturing rooms to be operated
independently. The specific facility design allows for the parallel manufacture of several
cell therapy products without the risk of mutual cross-contamination. A separate part
of the facility is furthermore specifically designed for the manufacture of products that
must meet special safety requirements with respect to genetic engineering or
protection against infection.
The operation of two separate and independent facilities provides maximum flexibility
and continuity in the manufacturing processes, especially for bridging regularly
scheduled maintenance periods. A major part of the new facility is already booked out
with manufacturing projects for various different clinical studies up to Phase III.
The staff consisting of 61 qualified employees currently handles both GMP facilities, the
associated projects and the comprehensive quality assurance system. These
professionals have profound expertise in the production and quality control of
autologous and allogeneic cell therapy products, process development, and the
validation of production processes as well as quality controls. The cleanroom capacities
of the Fraunhofer IZI shall again be expanded with a third construction section by mid-
2015 to meet the continuously growing demand in this business sector.
The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops
specific problem solutions at the interfaces of medicine, life sciences and engineering.
The Institute practices contract research for biotechnological, pharmaceutical and
medical-technological companies, hospitals, diagnostic laboratories and research
facilities. Within the Business Units of Agents, Cell Therapy, Diagnostic and Biobanking,
the Institute develops, optimizes and validates methods, materials and products. The
Institute's core competencies are located in the field of Regenerative Medicine, in
particular in the indication areas of oncology, ischemia and autoimmune, inflammatory
and infectious diseases. The Institute is clinically oriented and conducts quality checks
and the GMP-compliant manufacture of investigational medicinal products. Moreover,
the Institute provides support in obtaining manufacturing authorizations and approvals.
Research of practical utility lies at the heart of all activities pursued by the Fraunhofer-Gesellschaft. At present, the Fraunhofer-Gesellschaft
maintains 66 institutes and independent research units in Germany. More than 22,000 staff work with an annual research budget of €1.9 billion.
Of this sum, more than €1.6 billion is generated through contract research. More than 70 percent of the Fraunhofer-Gesellschaft’s contract
research revenue is derived from contracts with industry and from publicly financed research projects. Affiliated international research centers and
representative offices provide contact with the regions of greatest importance to present and future scientific progress and economic development.
Help employers find you! Check out all the jobs and post your resume.
comments powered by